Work

Preparation and Biological Evaluation of New Triterpenoid Derivatives of Glycyrrhetinic Acid

Year: 2022
Type: dissertation
Abstract: Cancer is a leading cause of death worldwide and its incidence is expected to increase significantly over the next decades. Despite the scientific progress in cancer research, the anticancer drugs currently in clinical use have several limitations in efficacy and safety. These data demonstrate the urgency to develop new chemotherapeutic drugs. Natural products have been the main source of new leads for anticancer drug development. In fact, some drugs derived from natural compounds are still the mainstay of cancer therapy. Pentacyclic triterpenoids are a group of natural compounds, widely distributed in plants, which display a broad range of biological activities, including antitumor activity. These compounds have been shown to modulate multiple signaling pathways and molecular targets of cancer, which increased their interest as leads for the development of new drugs. Glycyrrhetinic acid is a pentacyclic triterpenoid with a promising multi-target profile that can be extracted from its natural source in high quantities, which make it a commercially available and affordable lead. The main goal of this PhD thesis was the synthesis and the biological evaluation of new glycyrrhetinic acid derivatives, with the aim to improve its antitumor activity. The work followed two main semisynthetic strategies to modify the glycyrrhetinic acid scaffold: the introduction of different heterocyclic rings conjugated with an α,β- unsaturated ketone in its ring A, and the opening of the ring A along with the coupling of an amino acid moiety. The structures of the new derivatives were elucidated using different techniques, including infrared spectroscopy, mass spectrometry and nuclear magnetic resonance. The glycyrrhetinic acid derivatives were tested for their antiproliferative activity against several cancer lines. The most potent derivative of each series was also tested in the non tumoral BJ cell line, to evaluate their selectivity. The leukemia Jurkat cell line, in which the antiproliferative assays had the best results for both series, was selected to the execution of further biological assays. The most potent derivative of the first series was compound 2.9, which bears an imidazole ring conjugated to an α,β-unsaturated ketone in the ring A, has a reduced ring C and a methyl ester at C-30 position. This compound had an IC50 value of 1.1μM on Jurkat cells, which was 96-fold more potent than glycyrrhetinic acid and was also 4-fold more selective toward that cells. Further biological studies showed that compound 2.9 is a potent inducer of apoptosis that activates both the intrinsic and extrinsic pathways, as early as at 6 hours of treatment. In the second group of derivatives, compound 3.16, with a cleaved ring A, a reduced ring C and an alanine methyl ester chain at C-30 position, was the more active compound. It had an IC50 value of 6.1 μM on Jurkat cells, which was 17-fold more potent than that of glycyrrhetinic acid, and was up to 10 times more selective toward that cells. Preliminary mechanism investigation indicated that the antiproliferative activity of compound 3.16 was due to cell cycle arrest at the S phase and induction of apoptosis. Overall, this work contributed with two new panels of novel glycyrrhetinic acid derivatives with enhanced potency and selectivity that warrant to be further studied.
Language: Portuguese
Field: Chemistry
Open Access status: green
OpenAlex ID: W7042606228
Cites: 98
Cited by:
Related to: 10